Overview

A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis

Status:
Recruiting
Trial end date:
2025-05-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to describe the efficacy and safety of LY3454738 in adult participants with moderate-to-severe atopic dermatitis (AD).
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company